Purification and characterization of a glioma-derived growth factor
CA 2017379 C · Owner: Merck & Co. Inc. · Inventors: Thomas, Kenneth A. Jr.; Bayne, Marvin L.; Conn, Gregory L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Glioma-derived growth factor is purified from the culture media used to maintain mammalian glioma cells. The protein stimulates mitogenesis of mammalian vascular endothelial cells and is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 23, 1990 and granted June 25, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 23, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 23, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.